Frédéric Rouillon1, Lars Eriksson2, Benjaminas Burba3, Jiri Raboch4, Georgios Kaprinis5, Andreas Schreiner6. 1. 1 Department of Adult Psychiatry and INSERM Center 894, Sainte Anne Hospital University of Paris Descartes, Paris, France. 2. 2 Department of Forensic Psychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden. 3. 3 Psychiatry Department, Kaunas University of Medicine, Kaunas, Lithuania. 4. 4 Psychiatric Department, 1st Medical School, General University Hospital and Charles University, Prague, Czech Republic. 5. 5 Third Department of Psychiatry, Aristotle University of Thessaloniki, Thessaloniki, Greece. 6. 6 Medical Affairs EMEA, Janssen-Cilag GmbH, Neuss, Germany.
Abstract
OBJECTIVE:ConstaTRE is an open-label, randomised, controlled, relapse prevention trial in patients with stable schizophrenia or schizoaffective disorder switched torisperidone long-acting injectable (RLAI) or oral quetiapine, and was designed to test the hypothesis that injectable antipsychotic treatment with risperidone would be more effective than oral therapy with quetiapine. Here we report the functional recovery results from the ConstaTRE trial. METHODS: Clinically stable adults previously treated with oral risperidone, olanzapine, or oral first-generation antipsychotics were randomised to RLAI or quetiapine for 24 months. Functional recovery was assessed using the Social and Occupational Functioning Assessment Scale (SOFAS) and two quality-of-life (QoL) measures [Medical Outcomes Survey Short Form-12 (SF-12) and Schizophrenia Quality-of-Life Scale Revision 4 (SQLS-R4)]. RESULTS: A total of 666 patients were randomised and treated with RLAI (n = 329) or quetiapine (n = 337). Relapse occurred in 16.5% RLAI and 31.3% quetiapine patients. Significant improvements in SOFAS, SF-12, and SQLS-R4 scores were observed from baseline to month 24 with both RLAI and quetiapine. At months 6, and 12, and endpoint, improvement in SOFAS score was significantly greater for RLAI than quetiapine (p < 0.05). CONCLUSIONS: Among patients with stable schizophrenia or schizoaffective disorder, the likelihood of functional recovery appears to be higher in those switching to RLAI than to quetiapine, although improvements in functional status and QoL were observed with both treatments.
RCT Entities:
OBJECTIVE: ConstaTRE is an open-label, randomised, controlled, relapse prevention trial in patients with stable schizophrenia or schizoaffective disorder switched to risperidone long-acting injectable (RLAI) or oral quetiapine, and was designed to test the hypothesis that injectable antipsychotic treatment with risperidone would be more effective than oral therapy with quetiapine. Here we report the functional recovery results from the ConstaTRE trial. METHODS: Clinically stable adults previously treated with oral risperidone, olanzapine, or oral first-generation antipsychotics were randomised to RLAI or quetiapine for 24 months. Functional recovery was assessed using the Social and Occupational Functioning Assessment Scale (SOFAS) and two quality-of-life (QoL) measures [Medical Outcomes Survey Short Form-12 (SF-12) and Schizophrenia Quality-of-Life Scale Revision 4 (SQLS-R4)]. RESULTS: A total of 666 patients were randomised and treated with RLAI (n = 329) or quetiapine (n = 337). Relapse occurred in 16.5% RLAI and 31.3% quetiapinepatients. Significant improvements in SOFAS, SF-12, and SQLS-R4 scores were observed from baseline to month 24 with both RLAI and quetiapine. At months 6, and 12, and endpoint, improvement in SOFAS score was significantly greater for RLAI than quetiapine (p < 0.05). CONCLUSIONS: Among patients with stable schizophrenia or schizoaffective disorder, the likelihood of functional recovery appears to be higher in those switching to RLAI than to quetiapine, although improvements in functional status and QoL were observed with both treatments.
Authors: Diana Rofail; Antoine Regnault; Stéphanie le Scouiller; Carmen Galani Berardo; Daniel Umbricht; Ray Fitzpatrick Journal: Qual Life Res Date: 2015-07-05 Impact factor: 4.147
Authors: Marian S McDonagh; Tracy Dana; Shelley Selph; Emily B Devine; Amy Cantor; Christina Bougatsos; Ian Blazina; Sara Grusing; Rongwei Fu; Daniel W Haupt Journal: Psychiatr Res Clin Pract Date: 2020-10-16